Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMD

January 2, 2018 updated by: Dr. med. Katja Hatz, Vista Klinik

Time Course of Activity Signs at High Resolution OCT During OCT-guided High Frequency Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Age Related Macular Degeneration

The purpose of the study is to detect persisting or early new activity of choroidal neovascularization (CNV) due to age related macular degeneration (AMD) during the first 12 months following the first ranibizumab dose at baseline as assessed by weekly high resolution optical coherence tomography (OCT). Detection of persisting or new signs of CNV activity at OCT triggers further ranibizumab treatments considering that any ranibizumab injections can maximally be applied as often as 2-weekly.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This is a prospective, 1-arm, monocenter study designed to evaluate the time course of early re-activation of CNV assessed by High Resolution OCT. An OCT-guided high frequency (up to 2-weekly) intravitreal ranibizumab treatment in CNV due to AMD may prevent further growth and early re-growth of CNV as evaluated by OCT at a weekly basis.

Consenting, enrolled patients will receive one 0.5 mg ranibizumab intravitreal injection at baseline (month 0). Afterwards all patients will undergo a weekly OCT assessment. Further treatments, which can maximally be applied as often as 2-weekly, are triggered by persisting or new signs of CNV activity at OCT as defined by intraretinal cysts or subretinal fluid. For this study, a month is defined as 28 days, a 2-week period as 14 days. During the 12-month study period, a maximum of 24 ranibizumab injections may be administered.

An interim analysis will not be performed. The study will be conducted in compliance with the protocol, GCP and the applicable regulatory requirement(s).

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Switzerland
      • Binningen, Switzerland, 4102
        • Vista Klinik

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Male or female patients ≥ 50 years of age.
  • Patients with active primary subfoveal CNV secondary to AMD, including those with predominantly classic, minimally classic or occult lesions with no classic component.
  • Evidence that CNV extends under the geometric center of the foveal avascular zone.
  • Total CNV area encompassed within the lesion must be ≥ 50% of total lesion area.
  • The total lesion area ≤ 12 disc areas for minimally classic or occult with no classic component and ≤ 9 disc areas (5400µm) in greatest linear dimension with predominantly classic lesions.
  • Patients who have a BCVA of 20/32 to 20/320 (letter score of 78 to 25 letters) in the study eye using ETDRS charts.
  • Willing and able to give written informed consent according to legal requirements, and who have signed the consent form prior to initiation of any study procedure.
  • Willing and able to comply with study procedures.

Exclusion Criteria:

  • Subretinal hemorrhage in the study eye that involves the center of the fovea, if the size of the hemorrhage is either ≥ 50% of the total lesion area or ≥ 1 disc area in size.
  • Structural damage to the center of the macula (beside CNV) in the study eye.
  • Presence of a retinal pigment epithelial tear involving the macula in the study eye.
  • Patients with angioid streaks or precursors of CNV in either eye due to other causes.
  • Concurrent disease in the study eye that could compromise visual acuity or require medical or surgical intervention during the 12-month study period.
  • Vitreous hemorrhage, history of rhegmatogenous retinal detachment or macular hole.
  • Active intraocular inflammation (grade trace or above) in the study eye.
  • Any active infection involving ocular adnexa.
  • History of uncontrolled glaucoma in the study eye.
  • Aphakia with absence of the posterior capsule in the study eye.
  • Any prior treatment in the study eye with verteporfin, subfoveal focal laser photo-coagulation, vitrectomy, transpupillary thermotherapy, intravitreally applied drugs.
  • History of submacular surgery or other surgical intervention for AMD in the study eye.
  • Extracapsular extraction of cataract within 3 months preceding Baseline.
  • Previous violation of posterior capsule in the study eye (unless YAG capsulotomy).
  • History of Stroke.
  • Pregnant or nursing (lactating) women.
  • History of hypersensitivity or allergy to fluorescein.
  • Inability to obtain OCT/photographs/fluorescein angiograms of sufficient quality.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: prospective 1- Arm
OCT-guided high frequency intravitreal ranibizumab 0.5mg
Drug: Ranibizumab
Intravitreal injection
Other Names:
  • Lucentis

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in CNV activity (any fluid) as assessed by High Resolution OCT
Time Frame: 12 month OCT Assessment
The primary objective is to evaluate the time course of early re-activation of CNV assessed by High Resolution OCT.
12 month OCT Assessment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To evaluate the correlation between activation of CNV evaluated by OCT (any fluid) and changes of BCVA.
Time Frame: 12 month
► To evaluate the correlation between activation of CNV evaluated by OCT (any fluid) and changes of BCVA.
12 month
To evaluate the effect of OCT-guided up to 2-weekly dosing of ranibizumab on BCVA changes at month 12.
Time Frame: 12 months
To evaluate the effect of OCT-guided up to 2-weekly dosing of ranibizumab on BCVA changes at month 12.
12 months
To evaluate the effect of OCT-guided up to 2-weekly dosing of ranibizumab on the total number of injections needed within the 12 months observation period.
Time Frame: 12 months
To evaluate the effect of OCT-guided up to 2-weekly dosing of ranibizumab on the total number of injections needed within the 12 months observation period.
12 months
To evaluate the safety and tolerability of up to 2-weekly dosing of ranibizumab by determining the rates of adverse events and serious adverse events at month 12.
Time Frame: 12 months
To evaluate the safety and tolerability of up to 2-weekly dosing of ranibizumab by determining the rates of adverse events and serious adverse events at month 12.
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Vista Klinik

Investigators

  • Principal Investigator: Christian Pruente, MD, Vista Klinik

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2010

Primary Completion (Actual)

October 1, 2016

Study Completion (Actual)

December 1, 2016

Study Registration Dates

First Submitted

November 26, 2014

First Submitted That Met QC Criteria

January 2, 2018

First Posted (Actual)

January 8, 2018

Study Record Updates

Last Update Posted (Actual)

January 8, 2018

Last Update Submitted That Met QC Criteria

January 2, 2018

Last Verified

January 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • OCT-2010-07

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Age Related Macular Degeneration

Clinical Trials on Ranibizumab

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe